Amici Capital’s Theravance Biopharma TBPH Stock Holding History

Amici Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,705	Closed	-$207K	–	89
2016 Q3	$207K	Hold	5,705	–	–	0.05%	84
2016 Q2	$129K	Buy	+5,705	New	+$123K	0.02%	114
2015 Q4	–	Sell	-5,705	Closed	-$63K	–	131
2015 Q3	$63K	Hold	5,705	–	–	﹤0.01%	140
2015 Q2	$74K	Hold	5,705	–	–	﹤0.01%	132
2015 Q1	$99K	Buy	+5,705	New	+$105K	﹤0.01%	122

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amici Capital's TBPH Position: Q4 2016 in Review

Amici Capital sold out of Theravance Biopharma (TBPH) in Q4 2016, closing a stake of 5,705 shares — an estimated $207K sold.

Amici Capital first reported a position in TBPH in Q1 2015 and held it in 5 quarters. The position peaked at $207K in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

Amici Capital reported no remaining Theravance Biopharma position as of Q4 2016 after selling out during the quarter.
Amici Capital sold 5,705 Theravance Biopharma shares in Q4 2016, an estimated $207K.
Amici Capital first reported a position in Theravance Biopharma in Q1 2015 and held it in 5 quarters.
Amici Capital's Theravance Biopharma position peaked at $207K in Q3 2016.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on Amici Capital's 13F filing for Q4 2016, filed 14 Feb 2017.